(Q37658879)

21 August 2017

1 reference

title

Prophylactic HPV vaccines: the Finnish perspective (English)

1 reference

21 August 2017

0 references

1 reference

Kari J Syrjänen

1

1 reference

21 August 2017

publication date

1 January 2010

1 reference

Expert Review of Vaccines

21 August 2017

published in

1 reference

21 August 2017

volume

9

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

45-57

1 reference

Papillomaviruses in the causation of human cancers - a brief historical account

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Wart-virus antibodies and the prognosis of wart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Regression of warts. An immunological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Immunohistochemical demonstration of human papilloma virus (HPV) antigens in oral squamous cell lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Human papilloma virus (HPV) antigens in lesions of laryngeal squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Condylomatous changes in neoplastic bronchial epithelium. Report of a case

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

A controlled trial of a human papillomavirus type 16 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Prophylactic HPV vaccines: new interventions for cancer control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Integration of human papillomavirus vaccination and cervical cancer screening in Latin America and the Caribbean

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Cervical cancer screening following prophylactic human papillomavirus vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Recommendations for cervical cancer prevention in Asia Pacific

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

The intracluster correlation coefficient in cluster randomisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Persistent high-risk human papillomavirus infections and other end-point markers of progressive cervical disease among women prospectively followed up in the New Independent States of the Former Soviet Union and the Latin American Screening study co

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Annual disease burden due to human papillomavirus 16 and 18 infections in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

EUROGIN 2008 roadmap on cervical cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Integrating human papillomavirus vaccination in cervical cancer control programmes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Currently approved prophylactic HPV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

Broad-Spectrum Human Papillomavirus Vaccines: New Horizons but One Step at a Time

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.140

21 January 2018

Identifiers

DOI

10.1586/ERV.09.140

1 reference

21 August 2017

1 reference